BlackRock Discloses Significant Stake in Kiniksa Pharma
Ticker: KNSA · Form: SC 13G · Filed: 2024-01-25T00:00:00.000Z
Sentiment: bullish
Topics: institutional-ownership, SC-13G, pharmaceuticals
TL;DR
**BlackRock just confirmed its big stake in Kiniksa Pharma, a bullish sign for the stock.**
AI Summary
BlackRock, Inc., a major investment firm, reported its ownership in Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) as of December 31, 2023. This SC 13G filing indicates BlackRock holds a significant stake, signaling their continued confidence in the pharmaceutical company. For investors, this means a large institutional player is maintaining a position, which can be seen as a vote of confidence in Kiniksa's future prospects and stability.
Why It Matters
Large institutional ownership by firms like BlackRock can provide stability to a stock and signal to other investors that the company is a viable long-term investment.
Risk Assessment
Risk Level: low — This filing indicates a stable institutional ownership, which generally reduces volatility and risk for the stock.
Analyst Insight
A smart investor would view BlackRock's continued institutional ownership as a positive signal, suggesting stability and potential long-term value in Kiniksa Pharmaceuticals, Ltd., and might consider further research into KNSA's fundamentals.
Key Players & Entities
- BlackRock, Inc. (company) — the reporting person and institutional investor
- Kiniksa Pharmaceuticals, Ltd. (company) — the subject company whose shares are being reported
- December 31, 2023 (date) — the date of the event requiring the filing
Forward-Looking Statements
- BlackRock will maintain its significant stake in Kiniksa Pharmaceuticals, Ltd. throughout 2024. (BlackRock, Inc.) — medium confidence, target: December 31, 2024
FAQ
What type of filing is this document?
This document is an SC 13G filing, specifically filed under Rule 13d-1(b) of the Securities Exchange Act of 1934.
Who is the reporting person in this SC 13G filing?
The reporting person is BlackRock, Inc., identified by CIK 0001364742.
Which company's securities are being reported on?
The securities being reported on belong to Kiniksa Pharmaceuticals, Ltd., identified by CIK 0001730430.
What is the title of the class of securities held by BlackRock?
The title of the class of securities is "Class A Common Stock" of Kiniksa Pharmaceuticals, Ltd.
What was the date of the event that triggered this filing?
The date of the event which required the filing of this statement was December 31, 2023.
From the Filing
EDGAR Filing Documents for 0001086364-24-003309 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home Company Search Current Page Form SC 13G - Statement of Beneficial Ownership by Certain Investors: SEC Accession No. 0001086364-24-003309 Filing Date 2024-01-25 Accepted 2024-01-25 13:48:54 Documents 1 Document Format Files Seq Description Document Type Size 1 bmg5269c1010_012524.txt SC 13G 11704 Complete submission text file 0001086364-24-003309.txt 13532 Mailing Address 50 HUDSON YARDS NEW YORK NY 10001 Business Address 50 HUDSON YARDS NEW YORK NY 10001 212-810-5300 BlackRock Inc. (Filed by) CIK : 0001364742 (see all company filings) EIN. : 320174431 | State of Incorp.: DE | Fiscal Year End: 1231 Type: SC 13G SIC : 6211 Security Brokers, Dealers & Flotation Companies (CF Office: 02 Finance) Mailing Address CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11 Business Address CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11 7814399100 Kiniksa Pharmaceuticals, Ltd. (Subject) CIK : 0001730430 (see all company filings) EIN. : 000000000 | State of Incorp.: D0 | Fiscal Year End: 1231 Type: SC 13G | Act: 34 | File No.: 005-90491 | Film No.: 24561085 SIC : 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)